Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
Southpoint Capital Advisors LP announced that on Dec 24, 2025 it disposed of beneficial ownership of 1,000,000 common shares of Fennec Pharmaceuticals (TSX: FENC), representing approximately 2.93% of outstanding common shares on a fully diluted basis.
Rhea-AI Summary
Southpoint Capital Advisors LP announced that on Dec 24, 2025 it disposed of beneficial ownership of 1,000,000 common shares of Fennec Pharmaceuticals (TSX: FENC), representing approximately 2.93% of outstanding common shares on a fully diluted basis. The Common Shares were sold at USD $7.50 per share. After the disposition, Southpoint reports it now controls or directs 2.7 million common shares, representing about 8% of outstanding shares on a fully diluted basis. Southpoint said the shares were disposed for investment purposes and that it may change its ownership or control through market transactions, private agreements, treasury issuances, or exercise of warrants.
Positive
- Disposed of 1,000,000 shares at USD $7.50 per share
- Retains control of 2.7 million shares (~8% fully diluted)
Negative
- Beneficial ownership reduced by approximately 2.93% on Dec 24, 2025
Details
News Market Reaction – FENC
In the Dec 29 session, FENC declined 4.94%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Shares sold
- 1,000,000 shares
- Common shares disposed by Southpoint on Dec 24, 2025
- Stake sold
- 2.93%
- Portion of outstanding common shares on a fully diluted basis
- Sale price
- USD$7.50 per share
- Price for Southpoint’s common share disposal
- Remaining holding
- 2.7 million shares
- Common shares over which Southpoint retains control or direction
- Post-sale ownership
- 8%
- Approximate fully diluted ownership of outstanding common shares
Historical Context
-
Investigator-sponsored Phase I trial of PEDMARK in metastatic testicular tumors.
-
Positive Phase 2/3 PEDMARK study in Japan meeting primary endpoints.
-
Planned fireside chat at Piper Sandler healthcare conference.
-
Completion of full redemption of Petrichor convertible notes, leaving no debt.
-
Closing of Canadian private offering of common shares at $7.50 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
beneficial ownership financial
fully diluted basis financial
warrants financial
securities laws regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately
The Common Shares were sold at a price of USD
Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately
Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.
This press release has been issued in order to comply with applicable securities legislation.

For further information: Anthony J. Buffalano III Southpoint Capital Advisors LP 1114 Avenue of the Americas, 22nd Floor New York, NY 10036 Phone: (212) 692-6356
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.